Clinical Trials · NCT00444873

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Phase
Phase 3
Recruitment status
Completed
Sponsor
Ipsen
Enrollment
38
Start date
Jan 2005
Locations
1 site, Germany
Primary endpoint
Mean Insulin like Growth Factor 1 (IGF-1) and Growth Hormone (GH) levels at the beginning and end of the study and as proportion of patients conforming to internationally accepted levels.
View Lanreotide compound reference